The burden of diabetes and hyperglycemia in Brazil: a global burden of disease study 2017.
Adult
Age Distribution
Aged
Aged, 80 and over
Brazil
/ epidemiology
Cardiovascular Diseases
/ epidemiology
Diabetes Mellitus
/ epidemiology
Female
Global Burden of Disease
/ statistics & numerical data
Global Health
Humans
Hyperglycemia
/ epidemiology
Incidence
Male
Middle Aged
Prevalence
Quality-Adjusted Life Years
Residence Characteristics
Risk Factors
Sex Distribution
Socioeconomic Factors
Young Adult
Brazil
Diabetes mellitus
Global Burden of Disease
epidemiology
hyperglycemia
Journal
Population health metrics
ISSN: 1478-7954
Titre abrégé: Popul Health Metr
Pays: England
ID NLM: 101178411
Informations de publication
Date de publication:
30 09 2020
30 09 2020
Historique:
received:
15
05
2020
accepted:
19
06
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
2
9
2021
Statut:
epublish
Résumé
The Global Burden of Diseases (GBD) 2017 database permits an up-to-date evaluation of the frequency and burden of diabetes at the state level in Brazil and by type of diabetes. The objective of this report is to describe, using these updated GBD data, the current and projected future burden of diabetes and hyperglycemia in Brazil, as well as its variation over time and space. We derived all estimates using the GBD 2016 and 2017 databases to characterize disease burden related to diabetes and hyperglycemia in Brazil, from 1990 to 2040, using standard GBD methodologies. The overall estimated prevalence of diabetes in Brazil in 2017 was 4.4% (95%UI 4.0-4.9%), with 4.0% of those with diabetes being identified as having type 1 disease. While the crude prevalence of type 1 disease has remained relatively stable from 1990, type 2 prevalence has increased 30% for males and 26% for females. In 2017, approximately 3.3% of all disability-adjusted life years lost were due to diabetes and 5.9% to hyperglycemia. Diabetes prevalence and mortality were highest in the Northeast region and growing fastest in the North, Northeast, and Center-West regions. Over this period, despite a slight decrease in age-standardized incidence of type 2 diabetes, crude overall burden due to hyperglycemia has increased 19%, with population aging being a main cause for this rise. Cardiovascular diseases, responsible for 38.3% of this burden in 1990, caused only 25.9% of it in 2017, with premature mortality attributed directly to diabetes causing 31.6% of the 2017 burden. Future projections suggest that the diabetes mortality burden will increase 144% by 2040, more than twice the expected increase in crude disease burden overall (54%). By 2040, diabetes is projected to be Brazil's third leading cause of death and hyperglycemia its third leading risk factor, in terms of deaths. The disease burden in Brazil attributable to diabetes and hyperglycemia, already large, is predicted by GBD estimates to more than double to 2040. Strong actions by the Ministry of Health are necessary to counterbalance the major deleterious effects of population aging.
Sections du résumé
BACKGROUND
The Global Burden of Diseases (GBD) 2017 database permits an up-to-date evaluation of the frequency and burden of diabetes at the state level in Brazil and by type of diabetes. The objective of this report is to describe, using these updated GBD data, the current and projected future burden of diabetes and hyperglycemia in Brazil, as well as its variation over time and space.
METHODS
We derived all estimates using the GBD 2016 and 2017 databases to characterize disease burden related to diabetes and hyperglycemia in Brazil, from 1990 to 2040, using standard GBD methodologies.
RESULTS
The overall estimated prevalence of diabetes in Brazil in 2017 was 4.4% (95%UI 4.0-4.9%), with 4.0% of those with diabetes being identified as having type 1 disease. While the crude prevalence of type 1 disease has remained relatively stable from 1990, type 2 prevalence has increased 30% for males and 26% for females. In 2017, approximately 3.3% of all disability-adjusted life years lost were due to diabetes and 5.9% to hyperglycemia. Diabetes prevalence and mortality were highest in the Northeast region and growing fastest in the North, Northeast, and Center-West regions. Over this period, despite a slight decrease in age-standardized incidence of type 2 diabetes, crude overall burden due to hyperglycemia has increased 19%, with population aging being a main cause for this rise. Cardiovascular diseases, responsible for 38.3% of this burden in 1990, caused only 25.9% of it in 2017, with premature mortality attributed directly to diabetes causing 31.6% of the 2017 burden. Future projections suggest that the diabetes mortality burden will increase 144% by 2040, more than twice the expected increase in crude disease burden overall (54%). By 2040, diabetes is projected to be Brazil's third leading cause of death and hyperglycemia its third leading risk factor, in terms of deaths.
CONCLUSIONS
The disease burden in Brazil attributable to diabetes and hyperglycemia, already large, is predicted by GBD estimates to more than double to 2040. Strong actions by the Ministry of Health are necessary to counterbalance the major deleterious effects of population aging.
Identifiants
pubmed: 32993680
doi: 10.1186/s12963-020-00209-0
pii: 10.1186/s12963-020-00209-0
pmc: PMC7526086
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9Références
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
Diabetol Metab Syndr. 2014 Nov 18;6:123
pubmed: 25788987
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Endocr Rev. 2014 Aug;35(4):557-601
pubmed: 24483949
Lancet. 2015 Jun 20;385(9986):2534-45
pubmed: 25703108
Rev Bras Epidemiol. 2019 Oct 07;22Suppl 02(Suppl 02):E190006.SUPL.2
pubmed: 31596377
Diabetol Metab Syndr. 2016 Oct 13;8:70
pubmed: 27757172
Diabetes Metab. 2014 Feb;40(1):1-14
pubmed: 24262435
Diabetol Metab Syndr. 2017 Mar 14;9:18
pubmed: 28293304
Diabetes Care. 2011 May;34 Suppl 2:S210-4
pubmed: 21525457
Lancet. 2018 Nov 10;392(10159):1859-1922
pubmed: 30415748
Lancet. 2018 Nov 10;392(10159):1923-1994
pubmed: 30496105
Public Health Nutr. 2004 Feb;7(1A):101-21
pubmed: 14972056
Am J Public Health. 2014 Oct;104(10):e43-50
pubmed: 25121810
J Epidemiol Community Health. 2018 Sep;72(9):761-763
pubmed: 29540465
BMJ. 2017 Jan 4;356:i6538
pubmed: 28052845
Lancet. 2018 Nov 10;392(10159):2052-2090
pubmed: 30340847
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Lancet. 2018 Nov 10;392(10159):1684-1735
pubmed: 30496102
Public Health Nutr. 2015 Sep;18(13):2311-22
pubmed: 26205679
Lancet Glob Health. 2015 Nov;3(11):e712-23
pubmed: 26475018
J Public Health (Oxf). 2018 Jun 1;40(2):350-358
pubmed: 28525612
Am J Clin Nutr. 2016 Nov;104(5):1433-1440
pubmed: 27733404
Lancet. 2009 Nov 14;374(9702):1677-86
pubmed: 19878986
BMC Public Health. 2015 Aug 11;15:772
pubmed: 26259708
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
BMJ. 2014 Jul 15;349:g4485
pubmed: 25028385
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
BMJ Open. 2017 Nov 15;7(11):e017184
pubmed: 29146638
Lancet Diabetes Endocrinol. 2019 Apr;7(4):267-277
pubmed: 30803929
Public Health Nutr. 2018 Jan;21(1):18-26
pubmed: 28714422